Shopping Cart
Remove All
Your shopping cart is currently empty
VU590
Copy Product Info
😃Good
Catalog No. T23516Cas No. 313505-85-0
VU590 is a potent and moderately selective inhibitor of extrarenal medullary potassium ROMK (Kir1.1) that also inhibits Kir7.1 and modulates uterine myometrial contractility and melanocortin signalling.
VU590
Copy Product Info😃Good
Purity: 98.06%
Catalog No. T23516Cas No. 313505-85-0
VU590 is a potent and moderately selective inhibitor of extrarenal medullary potassium ROMK (Kir1.1) that also inhibits Kir7.1 and modulates uterine myometrial contractility and melanocortin signalling.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $38 | In Stock | In Stock | |
| 5 mg | $60 | In Stock | In Stock | |
| 10 mg | $98 | In Stock | In Stock | |
| 25 mg | $163 | In Stock | In Stock | |
| 50 mg | $247 | In Stock | In Stock | |
| 100 mg | $372 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:98.06%
Appearance:Solid
Color:Yellow
Contact us for more batch information
Product Introduction
VU590 AI Summary
VU590 exhibits a diverse range of bioactivities, making it a versatile candidate for various biomedical applications. It shows significant inhibitory activity against several targets including ROMK with an IC50 of 290 nM, rat ROMK1 in HEK293 cells with an IC50 of 294 nM, and human Kir7.1 with 69% inhibition at 10 µM. Additionally, it potently modulates Lamin A splicing, enhances SMN2 splice variant expression, and inhibits Tau fibril formation. VU590 also inhibits various enzymes and proteins such as Aldehyde Dehydrogenase 1 (ALDH1A1), Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase), JMJD2A-Tudor domain, Nrf2, Histone Lysine Methyltransferase G9a, BAZ2B, TGF-β, and human tyrosyl-DNA phosphodiesterase 1 (TDP1). The compound also shows bioactivities that include inhibiting the binding or entry into cells of Lassa Virus, Marburg Virus, and Hepatitis C Virus (HCV), and inducing synthetic lethality in tumor cells producing 2HG. It is also noted for its potential in antimalarial drug lead development by inhibiting AMA1-RON and MBNL1-poly(CUG) RNA binding, and for antiviral activity noted by a high throughput screening for Foot and Mouth Disease Virus antivirals. Additionally, VU590 exhibits moderate antiviral activity against SARS-CoV-2, including inhibition of the SARS-CoV-2 3CL-Pro protease (13.58% inhibition at 20 µM) and inhibition of SARS-CoV-2 induced cytotoxicity in VERO-6 cells at 10 µM. Lastly, it shows cytotoxic activity against human HepG2 cells with an IC50 of 10400 nM as per the CellTiter-Glo luminescent cell viability assay..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | VU590 is a potent and moderately selective inhibitor of extrarenal medullary potassium ROMK (Kir1.1) that also inhibits Kir7.1 and modulates uterine myometrial contractility and melanocortin signalling. |
| Targets&IC50 | Kir7.1:8 μM, Kir1.1:290 nM |
| Molecular Weight | 488.53 |
| Formula | C24H32N4O7 |
| Cas No. | 313505-85-0 |
| Smiles | Cl.Cl.[O-][N+](=O)c1ccc(CN2CCOCCOCCN(Cc3ccc(cc3)[N+]([O-])=O)CCOCC2)cc1 |
| Relative Density. | 1.216 g/cm3 (Predicted) |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
| Solubility Information | DMSO: < 20 mg/mL, Sonication is recommended. H2O: 1 mg/mL (2.05 mM), Sonication is recommended. | ||||||||||
Solution Preparation Table | |||||||||||
H2O
| |||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy VU590 | purchase VU590 | VU590 cost | order VU590 | VU590 chemical structure | VU590 formula | VU590 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.